Under the terms of the five-year deal, pharmaceutical company Ferrer will sell SelectMDx test directly to urologists in Spain.
The partners will use the GuardantOMNI assay, a 500-plus-gene liquid biopsy panel designed to accelerate clinical trials and targeted cancer therapy research.
The company said the planned commercial launch of its noninvasive lung cancer diagnostic has been delayed due to technical issues during the test's validation process.
The company had $1.1 million in revenue during the quarter, a 10 percent increase year over year despite what the firm said was a 15 to 20 percent sales reduction due to recent hurricanes.
Researchers are now using the approach to allow genome-wide sequencing to monitor disease and to investigate treatment response and resistance without the need for tissue biopsy.
The researchers found that most advanced EGFR-mutant lung cancer patients harbored changes in an average of two to three other oncogenes.
The company believes its system, launched earlier this year, can outperform other microfluidic technologies, yielding samples with fewer white blood cells that allow better genomic analyses.
The company is collaborating with two UK institutes to assess whether its Signatera ctDNA technology can detect disease recurrence in women treated for breast cancer.
The firm will advance an exosome isolation technology that it says allows for the capture of exosomes more efficiently and sensitively than existing platforms.
Unilabs will perform the test in Switzerland and offer it throughout its network of clinical labs in Europe, including France, the UK, Sweden, and other countries.
The New York Times profiles 23andMe's Anne Wojcicki and describes how she bounced back from a bad year.
Fotis Kafatos, the founding president of the European Research Council, has died, according to the Associated Press.
In PLOS this week: genomic analysis of honeybee disease, microRNA profiles of people with lupus nephritis, and more.
The Verge's Angela Chen tried out a gene test for fitness advice, but didn't learn much new information.